- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Calidi Biotherapeutics CEO Allan Camaisa verkauft Aktien im Wert von 16.200 US-Dollar | 3 | Investing.com Deutsch | ||
| 12.12. | Calidi Biotherapeutics prices $7.5M secondary offering | 1 | Seeking Alpha | ||
| 12.12. | Calidi Biotherapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 15.11. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 14.11. | Calidi Biotherapeutics announces pricing of $7.5M public offering of common stock | 2 | Seeking Alpha | ||
| 14.11. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock | 3 | GlobeNewswire (USA) | ||
| CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.11. | Pre-market Movers: California BanCorp, Harrow, Inc., Quantum Computing, BTC Digital, Calidi Biotherapeutics | 744 | AFX News | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.15 A.M. ET).In the Green California BanCorp. (BCAL) is up over 33% at $23.01.
Quantum... ► Artikel lesen | |
| 13.11. | Calidi Biotherapeutics plans stock offering | 2 | Investing.com | ||
| 13.11. | Calidi Biotherapeutics announces proposed offering | 2 | Seeking Alpha | ||
| 13.11. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Proposed Public Offering | 5 | GlobeNewswire (USA) | ||
| 13.11. | Calidi Biotherapeutics GAAP EPS of -$0.65 | 1 | Seeking Alpha | ||
| 13.11. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results | 91 | GlobeNewswire (Europe) | Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova (CLD-400), the company's systemic... ► Artikel lesen | |
| 12.11. | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.10. | NSE - Calidi Biotherapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 25.10. | Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 203 | ACCESSWIRE | ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small... ► Artikel lesen | |
| 23.10. | Why Calidi Biotherapeutics (CLDI) Stock Is Down 13% | 1 | Benzinga.com | ||
| 23.10. | CLDI stock touches 52-week low at $0.95 amid sharp annual decline | 3 | Investing.com | ||
| 23.10. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement | 2 | GlobeNewswire (USA) | ||
| 21.10. | Calidi Biotherapeutics warrants delist from NYSE | 3 | Seeking Alpha |
Seite:
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| QIAGEN | 42,900 | +0,04 % | Biotech Report: Evotec klettern, Qiagen leichter | (shareribs.com) Frankfurt / New York 16.12.2024 - Die Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Für Evotec ging es nach oben, während Qiagen und auch Biontech korrigierten. An der... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,52 | +5,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,990 | +6,24 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 8,405 | +1,08 % | Evotec-Aktie: Geht es jetzt weiter bergab - oder kommt doch noch in Kürze der große Durchbruch? Wir analysieren und verraten Ihnen unsere Tradingidee! | © Foto: SymbolbildWas passiert mit Evotec? Die Aktie des Hamburger Biotech-Unternehmens hatte 2024 kein einfaches Jahr: Fast 60 Prozent Kursverlust, Gerüchte über eine Übernahme und die Rückkehr in... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| CELCUITY | 12,460 | +3,83 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 13,500 | +1,12 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
| BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
| HUMACYTE | 4,635 | +33,77 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| AMGEN | 252,90 | +0,18 % | What's Going On With Amgen Stock On Friday? | ||
| JANUX THERAPEUTICS | 56,70 | -0,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 5,140 | +3,21 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
| IMMUNOVANT | 25,880 | +0,86 % | Immunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's Why | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
CALIDI BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,100 (-6,80 %) liegt der Kurs bei 1,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALIDI BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.
